Algamed Therapeutics

Company Overview

Snapshot

Founded in August 2014, Algamed Therapeutics operates with 1–10 employees. The company has raised $910,000 across two funding rounds. In September 2021, Algamed Therapeutics secured equity crowdfunding from PipelBiz.

Business overview

Algamed Therapeutics is a Health Tech & Life Sciences company focused on developing technologies to address common vaginal conditions such as dryness, infections, and dyspareunia. Its core product, Secret de Joie, is a natural, hormone-free jelly designed to treat vaginal dryness. The company serves women, including breast and ovarian cancer survivors, postmenopausal women, and those with diabetes, offering solutions in the pharmaceuticals sector.

Strategic signal

In November 2021, Algamed Therapeutics was highlighted for its innovative approach to femtech solutions, leveraging natural ingredients. This signals a strategic focus on natural and hormone-free treatments within women's health, positioning the company to address a significant market need, particularly for patients who cannot use hormone-based therapies.

Company Intelligence Q&A

What is Algamed Therapeutics' primary product?

Algamed Therapeutics' primary product is Secret de Joie, a natural, hormone-free jelly developed to treat vaginal dryness.

When was Algamed Therapeutics founded?

Algamed Therapeutics was founded in August 2014.

What was a significant funding event for Algamed Therapeutics?

In September 2021, Algamed Therapeutics secured equity crowdfunding from PipelBiz.

What market does Algamed Therapeutics primarily target?

Algamed Therapeutics primarily targets women experiencing vaginal dryness, including breast and ovarian cancer survivors, postmenopausal women, and those with diabetes, in markets such as the United States and Canada.

What is the total capital raised by Algamed Therapeutics?

Algamed Therapeutics has raised a total of $910,000 across two funding rounds.